Approaches to Protozoan Drug Discovery: Phenotypic Screening

被引:66
作者
Sykes, Melissa L. [1 ]
Avery, Vicky M. [1 ]
机构
[1] Griffith Univ, Eskitis Inst Drug Discovery, Nathan, Qld 4111, Australia
关键词
HIGH-THROUGHPUT ASSAY; TRYPANOSOMA-CRUZI; PLASMODIUM-FALCIPARUM; IN-VITRO; ANTITRYPANOSOMAL ACTIVITY; PARASITE PERSISTENCE; SLEEPING SICKNESS; 384-WELL FORMAT; VIABILITY ASSAY; BRUCEI;
D O I
10.1021/jm4004279
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Determining the activity of a compound and the potential impact on a diseased state is frequently undertaken using phenotypic or target-based approaches. Phenotypic screens have the advantage of the whole organism being exposed to the compound and thus all the targets and biological pathways associated with it. Cell penetration and access to targets in their "natural" environment are taken into account. Unless utilizing a genetically modified organism with an additional target associated indicator, elucidation of specific target(s) of active compounds is necessary. Target discovery is desirable to allow development of chemical entities based upon knowledge of the target structure. Phenotypic drug discovery has successfully identified new molecular entities for neglected protozoan disease research. In this perspective, the phenotypic approaches used to identify chemical entities for drug discovery and for use as tools against the parasites Plasmodium falciparum, Trypanosoma brucei brucei, and Trypanosoma cruzi will be outlined.
引用
收藏
页码:7727 / 7740
页数:14
相关论文
共 74 条
[1]   Plasmodium falciparum gametocytes: still many secrets of a hidden life [J].
Alano, Pietro .
MOLECULAR MICROBIOLOGY, 2007, 66 (02) :291-302
[2]   Activity In Vivo of Anti-Trypanosoma cruzi Compounds Selected from a High Throughput Screening [J].
Andriani, Grasiella ;
Chessler, Anne-Danielle C. ;
Courtemanche, Gilles ;
Burleigh, Barbara A. ;
Rodriguez, Ana .
PLOS NEGLECTED TROPICAL DISEASES, 2011, 5 (08)
[3]   Myocardial parasite persistence in chronic Chagasic patients [J].
Añez, N ;
Carrasco, H ;
Parada, H ;
Crisante, G ;
Rojas, A ;
Fuenmayor, C ;
Gonzalez, N ;
Percoco, G ;
Borges, R ;
Guevara, P ;
Ramirez, JL .
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 1999, 60 (05) :726-732
[4]  
[Anonymous], 2004, WORLD HLTH REP
[5]  
[Anonymous], 2011, STUD US OR POS POS T
[6]   The global pipeline of new medicines for the control and elimination of malaria [J].
Anthony, Melinda P. ;
Burrows, Jeremy N. ;
Duparc, Stephan ;
JMoehrle, Joerg ;
Wells, Timothy N. C. .
MALARIA JOURNAL, 2012, 11
[7]   CHANGES IN FIBROBLAST-DERIVED TRYPOMASTIGOTES OF TRYPANOSOMA-CRUZI DURING LONG-TERM CULTURE [J].
ASHRAF, M ;
KUHN, RE .
JOURNAL OF PARASITOLOGY, 1992, 78 (03) :526-528
[8]   Phylogeography and Taxonomy of Trypanosoma brucei [J].
Balmer, Oliver ;
Beadell, Jon S. ;
Gibson, Wendy ;
Caccone, Adalgisa .
PLOS NEGLECTED TROPICAL DISEASES, 2011, 5 (02)
[9]   High-throughput Plasmodium falciparum growth assay for malaria drug discovery [J].
Baniecki, Mary Lynn ;
Wirth, Dyann F. ;
Clardy, Jon .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2007, 51 (02) :716-723
[10]   Human African trypanosomiasis: pharmacological re-engagement with a neglected disease [J].
Barrett, M. P. ;
Boykin, D. W. ;
Brun, R. ;
Tidwell, R. R. .
BRITISH JOURNAL OF PHARMACOLOGY, 2007, 152 (08) :1155-1171